Partial
Partially Aligned
Patient Risk:
Moderate
Summary
One label-consistent claim was supported (weight-neutral/ not indicated for weight loss). However, the overall response contains multiple non-label claims about illicit purchasing and out-of-pocket costs and does not align well with the provided FDA prescribing information excerpts for EGRIFTA SV.
Category Scores
Accurate Statements
Egrifta is not indicated for weight loss management as it has a weight neutral effect.
1 INDICATIONS AND USAGE (Limitations of Use): “EGRIFTA SV is not indicated for weight loss management as it has a weight neutral effect.”
Unsupported Statements
The assistant cannot provide black-market pricing for Egrifta or other prescription drugs.
Not addressed in the provided FDA prescribing information excerpts.
Sharing prices for illicit sales could meaningfully enable illegal drug trafficking.
Not addressed in the provided FDA prescribing information excerpts.
Out-of-pocket cost for Egrifta can vary depending on insurance coverage and any copay requirements.
Not addressed in the provided FDA prescribing information excerpts.
Out-of-pocket cost for Egrifta can vary depending on whether you use an authorized pharmacy or a specialty pharmacy.
Not addressed in the provided FDA prescribing information excerpts.
Out-of-pocket cost for Egrifta can vary depending on availability of patient assistance or manufacturer programs (when offered).
Not addressed in the provided FDA prescribing information excerpts.
Out-of-pocket cost for Egrifta can vary depending on dose and treatment duration.
Not addressed in the provided FDA prescribing information excerpts.
If counterfeit or diverted Egrifta is used, dosing accuracy, sterility, and ingredient identity are not reliable.
Not addressed in the provided FDA prescribing information excerpts.
Using counterfeit or diverted Egrifta can be extremely risky.
Not addressed in the provided FDA prescribing information excerpts.
The safest route to avoid counterfeit/gray-market risk is using a licensed prescriber and an authorized pharmacy.
Not addressed in the provided FDA prescribing information excerpts.
Contradictions
Low
AI Statement
Egrifta is also known as tesamorelin.
Label Reference
No contradictory statement in the provided excerpts; however, the label provided here does not explicitly state a synonym/brand-to-active-name equivalence in the excerpted text beyond listing the active ingredient as tesamorelin. Rated as low-severity potential mismatch for audit purposes.
Important Omissions
No evaluation (in the provided response content) of EGRIFTA SV contraindications, boxed warnings (if any), warnings/precautions, drug interactions, adverse reactions, or required monitoring as described in the supplied label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Non-label guidance about illicit/counterfeit procurement and out-of-pocket cost variation is not supported by the provided FDA prescribing information excerpts; additionally, major safety sections of the label were not evaluated.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most statements are not supported by the provided EGRIFTA SV prescribing information excerpts; only the weight-neutral/weight loss limitation aligns with the label.
Suggested Improvement
Restrict conclusions to label-supported content (indication/limitations, dosing instructions, contraindications, warnings/precautions, interactions, adverse reactions, and monitoring) and avoid unsupported claims about pricing/counterfeits that are not addressed in the provided excerpts.